Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$5.00 USD
-0.14 (-2.72%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $5.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
EDIT 5.00 -0.14(-2.72%)
Will EDIT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EDIT
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Other News for EDIT
Commit To Buy Editas Medicine At $2.50, Earn 14% Using Options
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
Earnings week ahead: MSFT, AMZN, AAPL, META, PFE, MCD, SBUX, XOM, CVX and more
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition